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Abstract
Introduction Intensive care unit (ICU) admission for bone
marrow transplant recipients immediately following
transplantation is an ominous event, yet the survival of these
patients with subsequent ICU admissions is unknown. Our
objective was to determine the long-term outcome of bone
marrow transplant recipients admitted to an ICU during
subsequent hospitalizations.
Methods We conducted a population-based cohort analysis of
all adult bone marrow transplant recipients who received
subsequent ICU care in Ontario, Canada from 1 January 1992
to 31 March 2002. The primary endpoint was mortality at 1 year.
Results A total of 2,653 patients received bone marrow
transplantation; 504 of which received ICU care during a
subsequent hospitalization. Patients receiving any major
procedure during their ICU stay had higher 1-year mortality than
those patients who received no ICU procedure (87% versus
44%, P < 0.0001). Death rates at 1 year were highest for those
receiving mechanical ventilation (87%), pulmonary artery
catheterization (91%), or hemodialysis (94%). In combination,
the strongest independent predictors of death at 1 year were
mechanical ventilation (odds ratio, 7.4; 95% confidence interval,
4.8 to 11.4) and hemodialysis (odds ratio, 8.7; 95% confidence
interval, 2.1 to 36.7), yet no combination of procedures
uniformly predicted 100% mortality.
Conclusion The prognosis of bone marrow transplant
recipients receiving ICU care during subsequent
hospitalizations is very poor but should not be considered futile.
Introduction
Bone marrow transplantation is a heroic element of therapy for
leukemia, lymphoma, and some other devastating diseases.
The procedure sometimes yields improved long-term survival,
yet it can entail significant morbidity during the initial recovery
[1-3]. About 40% of patients receive intensive care unit (ICU)
treatment with the initial transplant [4]. The specific reasons
for ICU admission frequently involve pulmonary, hepatic, or
neurological dysfunction [5-8]. In addition to monitoring tech-
niques such as continuous blood pressure recording, ICU
care often involves complicated treatment including mechani-
cal ventilation, renal replacement therapy, and continuous
medication infusions.
The utility of expensive ICU treatments for bone marrow trans-
plant recipients is uncertain (Additional File 1). Two studies
recruited patients prospectively [9,10], whereas most past
research is based on retrospective cohort studies. Only two
prior studies involved multiple centers [9,11]. All studies have
concentrated on short-term outcomes following ICU admis-
sion during the early post-transplant period. Most studies of
patient outcomes following ICU admission in bone marrow
transplant recipients measured only hospital mortality,
although five studies reported 6-month survival [12-16] and
one study reported 1-year survival [11]. Almost all prior studies
have a small sample size.
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Authorities suggest that ICU admission following bone mar-
row transplantation is associated with a poor prognosis
[17,18]. No study, however, has examined whether the poor
prognosis extends to subsequent hospitalizations. Further-
more, greater knowledge of long-term outcomes would be
useful to policymakers, ethicists, and other stakeholders
[19,20]. The universal healthcare system in Ontario provides a
unique opportunity to study long-term outcomes of unusual
conditions across multiple study centers and for an entire pop-
ulation. We therefore used the Ontario health databases to
evaluate survival of bone marrow transplant patients admitted
to the ICU. Whereas previous research focused on outcomes
of patients requiring ICU at the time of transplant, we exam-
ined the ICU stay during subsequent hospital admissions.
Methods
Identification of bone marrow transplant
We identified all adults (age > 18 years) who underwent bone
marrow transplant in the province of Ontario using the Ontario
Health Insurance Plan database. This database contains fee-
for-service claims for services provided by physicians to
Ontario residents [21,22]. The study period spanned 1 Janu-
ary 1992 to 31 March 2002, representing all years for which
data were available. There were no exclusion criteria for the
present study.
Bone marrow transplant recipients were linked to the Cana-
dian Institute for Health Information Discharge Abstract Data-
base, which contains demographic data, administrative data,
and clinical data for hospital discharges and day surgeries in
Canada. Individuals were also linked to the Registered Per-
sons Database, which contains vital statistics on Ontario citi-
zens. These databases have been used extensively in past
research [23-26].
The admission containing the most recent discharge date was
retained when multiple records had the same unique patient
identifier, admission date, and date of birth. If multiple bone
marrow transplants were performed on the same patient, we
only considered the first procedure. If duplicate records were
identical for unique patient identifier and admission date, the
record associated with the most recent discharge date was
retained. If discharge dates were also identical, one of the
records was randomly deleted.
Identification of subsequent ICU admission
We identified admissions to the ICU using codes in the
Ontario Health Insurance Plan database according to a previ-
ously described algorithm [27]. The Ontario Health Insurance
Plan database contains all claims submitted to the single-
payer healthcare system for reimbursement for physician serv-
ices. We focused on the first ICU admission following the hos-
pital discharge for bone marrow transplantation. When ICU
codes were interrupted by >1 day, we assumed the patient
had been discharged and then readmitted to the ICU. We
identified ICU admissions diagnosed as a complication of
bone marrow transplant using the corresponding International
Classification of Diseases, Ninth Revision, Clinical Modifica-
tion Code (996.8); this code does not distinguish between
graft versus host disease and other complications of bone
marrow transplant. Similarly, we identified the diagnoses of
acute renal failure (Codes 584.5, 584.6, 584.7, 584.8 and
584.9) and acute hepatic failure (Codes 570, 573.3, 572.2,
572.4, 782.4 and 286.7) during the hospital stay using previ-
ously described code combinations [28,29].
We identified common procedures using codes available in
the Ontario Health Insurance Plan database. Mechanical ven-
tilation was identified using a previously described algorithm
[27]. We defined pulmonary artery catheter use by the pres-
ence of the specific code for this procedure during the ICU
admission. Similarly, patients who had codes for acute hemo-
dialysis were defined as receiving renal replacement therapy.
Analysis
The primary outcome was mortality at 1 year. The end of the
observation period was 31 March 2003, so that all patients
were followed for at least 1 year. We analyzed the frequency
of death using the chi-square test. Odds ratios and 95% con-
fidence intervals (CIs) were estimated using univariate logistic
regression. We decided in advance to stratify patients into cat-
egories based on the following characteristics: autologous
versus allogeneic bone marrow transplant; need for mechani-
cal ventilation; provision of mechanical ventilation for >10
days; receipt of hemodialysis; and insertion of a pulmonary
artery catheter.
Life tables were constructed to create Kaplan–Meier curves
for survival and for ICU-free survival. For the Kaplan–Meier
analysis of ICU-free survival, we considered the event to be
admission to the ICU following hospitalization for bone marrow
transplant. Patients were censored at the end of follow up or
at death. All P values were two-tailed and analyses were con-
ducted using SAS software (version 9.13; SAS Institute Inc.,
Cary, NC, USA).
Ethics
The need for informed consent was waived for this analysis of
administrative health data. The study was approved by the eth-
ics committee of the Sunnybrook Health Sciences Centre and
was conducted using confidentiality safeguards at the Institute
for Clinical Evaluative Sciences in Ontario.
Results
We identified 2,653 patients who underwent a first bone mar-
row transplant during the study, of whom 60% received allo-
geneic transplants (Table 1). The underlying diagnosis was
malignancy in most cases. Almost all of the procedures (n =
2,631; 99%) were performed at seven different centers
(range, 45 to 1,543 transplants per center), and noAvailable online http://ccforum.com/content/12/3/R77
Page 3 of 9
(page number not for citation purposes)
association was apparent between 1-year mortality and the
bone marrow transplant procedure volume (Spearman's rank
correlation ρ = 0.14, P = 0.76). Only 175 (6.6%) patients died
during the initial bone marrow transplant hospitalization. On
average, survivors required hospitalization 1.2 times (median,
1.0; interquartile range, 0 to 2) during the first year following
transplant and 2.2 times during the entire study period
(median, 1.0; range, 0 to 20; interquartile range, 0 to 3). Dur-
ing these subsequent hospital admissions, 504 (20%)
patients received ICU care – typically (351 patients; 70%)
during the first year following the original transplant procedure
(Figure 1).
The median time from the original transplant discharge to sub-
sequent ICU admission was 124 days (interquartile range, 24
to 584 days). The frequencies of ICU admission comparing
autologous bone marrow transplant recipients with allogeneic
recipients were similar in the long run (Figure 1). The mean age
was 43 years (standard deviation, 11 years), and the median
length of the first ICU stay was 4 days (interquartile range, 2
to 10 days). The main reasons for hospital admission varied
but included infection (n = 82, 16%), respiratory failure (n =
72, 14%), and cardiac failure (49 patients, 9.7%) (Table 2).
One-third of patients (n = 154) were admitted with a compli-
cation of the bone marrow transplant (including graft versus
host disease), although this was rarely the most responsible
diagnosis (n = 30). Acute renal failure developed in about one
in five patients (n = 97), whereas acute hepatic failure was rare
(n = 17). Few of the patients (n = 66) received a second bone
marrow transplant during this subsequent hospitalization.
Specific procedures
Mechanical ventilation at any time during subsequent hospital-
izations was provided to about one-half (n = 258) of 504 bone
marrow transplant recipients admitted to the ICU, but was
rarely continued for >10 days (n = 67; Table 3). Hemodialysis
during the ICU stay was provided to 35 (6.9%) patients, and
pulmonary artery catheterization to 94 (19%) patients. Multiple
procedures were frequently performed; for example, 86 (33%)
mechanically ventilated patients also received pulmonary
artery catheterization and 29 (11%) mechanically ventilated
patients also received hemodialysis.
Outcomes following ICU admission
Mortality 1 year following ICU admission (Table 4) was not sig-
nificantly related to the type of transplant (autologous 70%
versus allogeneic 66%, P = 0.33) and was similar comparing
early study years (January 1992 to March 1998, 69%) with
later years (April 1998 to March 2002, 66%; P  = 0.59).
Longer intervals between bone marrow transplant and ICU
admission decreased the 1-year risk of dying (odds ratio, 0.73;
95% confidence interval, 0.65 to 0.83) for each additional year
between hospitalizations (P < 0.0001). The mean years from
transplant to subsequent ICU admission was two times longer
Table 1
Characteristics of patients with and without intensive care unit admission following bone marrow transplant hospitalization
All patients 
(n = 2,653)
No ICU admission following BMT 
hospitalization 
(n = 1,974)a
ICU admission during 
subsequent hospitalizations 
(n = 504)
P valueb
Age (standard deviation) at BMT (years) 44 (12) 44 (12) 43 (11) 0.04
Female gender (%) 1,221(46) 907 (46) 217 (43) 0.24
Allogeneic BMT (%) 1,583(60) 1,215 (62) 264 (52) 0.0002
ICU stay during BMT admission (%) 2,544(96) 1,877 (95) 496 (98) 0.013
Mechanical ventilation during BMT admission (%) 181 (7.1) 31 (2.0) 54 (11) <0.0001
Length of hospital stay (standard deviation) during 
BMT admission (days)
32 (21) 31 (20) 33 (19) 0.0028
Physician claims (standard deviation) during 3 years 
preceding BMT admission
151 (83) 145 (74) 172 (107) <0.0001
Charlson score > 2 during BMT hospitalization (%) 150 (5.6) 128 (6.0) 12 (2.0) 0.0004
Malignancy 2,582(97) 1,920 (97) 492 (98) 0.66
Leukemia 948 (36) 620 (31) 227 (45) <0.0001c
Lymphoma 831 (31) 666 (34) 125 (25)
Multiple myeloma 461 (17) 364 (18) 86 (17)
Breast cancer 151 (5.7) 131 (6.6) 15 (3.0)
aExcludes the 175 patients who died during bone marrow transplant (BMT) admission.
bFor comparison of patients with versus patients without intensive care unit (ICU) admission following bone marrow transplantation hospitalization.
cFor comparison of patients with versus patients without ICU admission following bone marrow transplantation across subtypes of malignancy.Critical Care    Vol 12 No 3    Scales et al.
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for survivors than for decedents (1.6 versus 0.8, P < 0.0001).
Patients admitted to hospital for complications of the bone
marrow transplant (including graft versus host disease) had
particularly high mortality at 1 year (81%; 95% confidence
interval, 73% to 86%). As expected, mortality at 1 year was
also high for patients who developed acute renal failure (89%;
95% confidence interval, 81% to 94%) or acute hepatic failure
(71%; 95% confidence interval, 44% to 90%).
Most patients died within the first year after ICU admission,
whereas survival declined only modestly during subsequent
years (Figure 2). Patients receiving any ICU procedure had
higher 1-year mortality than those patients not receiving a pro-
cedure (87% versus 44%, P < 0.0001). Death at 1 year was
specifically more frequent if patients required mechanical ven-
tilation (87%; 95% confidence interval, 82% to 91%), pulmo-
nary artery catheterization (91%; 95% confidence interval,
84% to 96%), or hemodialysis (94%; 95% confidence inter-
val, 81% to 99%). Only about 7% of patients who were
mechanically ventilated for 10 days or longer survived, and all
16 mechanically ventilated patients who received multiple ICU
admissions during the same hospitalization died. Exactly eight
patients receiving hemodialysis during their ICU stay required
chronic hemodialysis during the subsequent year. The strong-
est independent predictors of death were mechanical ventila-
tion and hemodialysis (Table 5). Multivariable regression
analysis could not be completed because of the small number
of survivors in each stratum.
We further examined survivors of multiple procedures during
ICU admission. Eight survivors received mechanical ventilation
plus either pulmonary artery catheterization or hemodialysis. In
this subgroup the median time interval between bone marrow
transplant and ICU admission was 1.3 years (interquartile
range, 0.36 to 4.5 years). The median ICU length of stay was
6.5 days (interquartile range, 2.0 to 31 days). The survivors'
mean age was 45 years (standard deviation, 7.3 years) and
most survivors (n = 7) were male.
Figure 1
Time from bone marrow transplant to intensive care unit admission Time from bone marrow transplant to intensive care unit admission. Kaplan–Meier curves showing outcomes following bone marrow transplant 
(BMT) hospitalization. y axis, percentage of original cohort remaining event-free following discharge from BMT (n = 2,653); x axis, time in years from 
BMT discharge. Curves represent patients still alive following BMT hospitalization (no deaths, lower curves) and patients remaining free of the inten-
sive care unit (ICU) following BMT hospitalization (censoring both deaths and patients lost to follow up) (no subsequent ICU, upper curves). Black 
lines, survival following autologous BMT; gray lines, survival following allogeneic BMT.Available online http://ccforum.com/content/12/3/R77
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Discussion
We studied 2,653 consecutive patients undergoing bone mar-
row transplant over a decade in Ontario and found that ICU
admission during subsequent hospitalizations is associated
with high mortality (67%). Mortality rates in this cohort were
similar to those observed immediately post-transplant, but
attenuated slightly as the time interval since the initial trans-
plant increased. Death rates at 1 year were highest amongst
patients requiring aggressive ICU treatments such as mechan-
ical ventilation (87%), pulmonary artery catheterization (91%),
and hemodialysis (94%). We could find no combination of ICU
procedures that would uniformly predict death, and survival
rates did not vary substantially considering multiple
procedures.
Outcomes following ICU procedures in our study are similar to
those previously reported for the early post-transplant period:
the pooled mortality in 21 studies of mechanical ventilation
during the early post-transplant period was 90% (1,974 of
2,183 patients; range, 55% to 100%), in four studies of acute
renal failure was 78% (104 of 134 patients; range 69% to
100%), and in one study reporting pulmonary artery catheter-
ization was 86% (18 of 21 patients) (Additional File 1). In
Ontario, most patients (96%) were admitted to a bone marrow
transplant special care unit during this early transplant period.
We are unable to determine reasons why 4% of bone marrow
transplant recipients were not admitted to these units. Our
results show that ICU care continues to be associated with a
poor prognosis years after the time of the initial bone marrow
transplant.
Investigators have proposed strategies for identifying futile sit-
uations for bone marrow transplant recipients on the basis of
multiple adverse characteristics [9]. The largest such study
observed no survivors amongst 398 patients who had acute
lung injury and who had either received more than 4 hours of
therapy with vasoactive medications or sustained hepatic and
renal failure [30]. We were unable to test this nuance because
data about these clinical combinations were not available in
this large sample size of patients.
Previous studies documenting 100% mortality in some sub-
groups have stimulated recommendations to restrict intensive
care for selected bone marrow transplant recipients [18,31].
These subgroups tend to be small, however, limiting the preci-
sion of survival estimates. Other authors suggest that physi-
cians forego treatment if success is attainable in fewer than
one in 100 cases [32]; however, no subgroup in our study ful-
filled this quantitative threshold for futility. Examining specific
Table 2
Most responsible diagnosis for bone marrow transplant 
recipients requiring intensive care unit during subsequent 
hospitalizations
Most responsible diagnosis n (%)
Hematological/lymphatic malignancy 186 (37)
Infectiona 82 (16)
Respiratory failure 72 (14)
Cardiac disease 49 (9.7)
Complication of bone marrow transplant 30 (5.9)
Hematologic abnormality 19 (3.7)
Gastrointestinal disorder 16 (3.2)
Solid tumor 11 (2.2)
Renal disorder 7 (1.4)
Other 17 (3.4)
aIncludes pneumonia.
Table 3
Bone marrow transplant recipients requiring mechanical ventilation during subsequent hospitalizations
Dieda (n = 224) Survived (n = 34)
Demographics
Mean (standard deviation) age (years) 43 (12) 44 (10)
Female sex (%) 45 26
Type of bone marrow transplant
Allogeneic transplant (%) 48 59
Autologous transplant (%) 52 41
Intensive care unit procedures
Mechanical ventilation > 10 days (%) 28 15
Pulmonary artery catheterization (%) 35 21
Hemodialysis (%) 12 6
aDied within 1 year of intensive care unit admissionCritical Care    Vol 12 No 3    Scales et al.
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subgroups of bone marrow transplant recipients to identify
characteristics that reliably predict survival rates < 1%
requires an enormous sample size.
The results from our large study support the concept that ICU
care should not be systematically withheld from bone marrow
transplant recipients [33]. We detected survivors in each of
our prespecified strata, including patients receiving multiple
procedures and those requiring prolonged mechanical ventila-
tion. The number needed to treat in the ICU to save one life at
1 year was never greater than 20 for any subgroup. This effect
size would be considered adequate to justify inexpensive ther-
apies [34]. Moreover, our study reflects some care from more
than a decade ago, suggesting that future technology
improvements may make future prognoses even better [19].
Our retrospective study lacks information on several factors
that might influence prognosis, such as the specific reason for
ICU admission, the degree of acute physiological disturbance,
and the use of other ICU procedures or medications. The
strength of our study is its large sample size and multicenter
recruitment [30]. Our extended observation interval also indi-
cates that advances in the care of bone marrow transplant
patients may have improved their prognosis in the community
[30,35], yet we detected no such trend in the ICU.
Previous research has reported greater complication rates and
mortality with allogeneic bone marrow transplants compared
with autologous transplants [36-40]. Contrary to these previ-
ous studies, our research does not show a short-term survival
benefit with autologous bone marrow transplantation. Instead,
the probable explanation for the observed survival differences
(Figure 1) is probably different indications and severity of dis-
ease, as was typically controlled for in other smaller studies.
These nuances may be the core reason why ICU survival and
medical futility are so difficult to predict. No standardized
admission criteria for bone marrow transplant recipients
existed, so our databases cannot explain decisions to provide
or withhold ICU admission from specific subgroups of patients
(including type of transplant). Finally, our database lacked
information regarding other long-term outcomes that might be
important to ICU survivors such as the health-related quality of
life, functional status, or ongoing care requirements, which
remain a topic for future research [41,42].
Table 4
Outcomes of bone marrow transplant recipients admitted to the intensive care unit
All ICU patients Mechanical ventilation Pulmonary artery catheter Hemodialysis
Number (%a)D i e d b (%) Number (%) Died (%) Number (%) Died (%) Number (%) Died (%)
BMT special care unit during first 
BMT hospitalization
2,544 (96) 734 (29) 181 (7.1) 146 (81) 74 (2.9) 65 (88) 73 (2.9) 51 (70)
ICU within first year after BMT 
hospitalization
351 (13) 261 (74) 202 (58) 183 (91) 78 (22) 74 (95) 24 (6.8) 23 (96)
ICU within first 3 years after BMT 
hospitalization
450 (17) 317 (70) 241 (54) 214 (89) 86 (19) 81 (94) 29 (6.4) 28 (97)
ICU anytime during study period after 
BMT hospitalization
504 (19) 340 (67) 258 (51) 224 (87) 94 (19) 86 (91) 35 (6.9) 33 (94)
aPercentage of total (n = 2,653) bone marrow transplant (BMT) patients.
bDied within 1 year of intensive care unit (ICU) admission.
Table 5
Outcomes following specific intensive care unit procedures
Number Dieda (%) Odds ratiob (95% confidence interval)
Mechanical ventilation alone 258 224 (87) 7.4 (4.8 to 11.4)
Mechanical ventilation > 10 days 67 62 (93) 7.1 (2.8 to 18.0)
Pulmonary artery catheterization 94 86 (91) 6.6 (3.1 to 14.0)
Hemodialysis 35 33 (94) 8.7 (2.1 to 36.7)
Mechanical ventilation and pulmonary artery catheterization 86 79 (92) 6.8 (3.0 to 15.1)
mechanical ventilation and hemodialysis 29 27 (93) 7.0 (1.6 to 29.8)
Pulmonary artery catheterization and hemodialysis 12 11 (92) 5.4 (0.7 to 42.6)
aDeath within 1 year of intensive care unit (ICU) admission.
bComparison is with all patients without specified procedures or combinations of procedures.Available online http://ccforum.com/content/12/3/R77
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Conclusion
Defining futile situations requires a large sample size to estab-
lish that good outcomes are sufficiently infrequent. In addition,
quantifying such thresholds is somewhat arbitrary and
requires consensus amongst stakeholders. The detection of
survivors in every stratum of our cohort suggests that ICU care
for bone marrow transplant recipients should not be consid-
ered futile, contrary to popular opinion or economic incentives.
Our results can be used to counsel patients and family mem-
bers about prognosis and guiding ICU care for bone marrow
transplant recipients who consider these therapies to be
appropriate.
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